Oliver Mobasser

  • 99 Bishopsgate
  • London EC2M 3XF
  • United Kingdom

Oliver Mobasser is an associate in the London office. Mr. Mobasser has particular expertise in the healthcare and life sciences sectors, advising multinational pharmaceutical, biotechnology and medical technology companies and their investors on complex licenses, collaborations, acquisitions, divestments, commercial contracts, intellectual property matters, and regulatory and privacy matters.

Prior to joining Latham, Mr. Mobasser was a solicitor at a leading firm in Dublin, Ireland, as well as completing a secondment as in-house counsel for Shire Pharmaceuticals in 2017/2018.

Mr. Mobasser’s experience covers:

  • Life sciences regulation
  • Product licensing and acquisitions
  • Technology transactions
  • Intellectual property
  • Commercial contracts and collaborations
  • Data protection

Mr. Mobasser’s experience includes advising:

  • GSK on a variety of matters, including:
    • Its strategic global collaboration and licensing agreement with Alector for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease
    • Various early-stage collaboration, development, and supply arrangements 
    • The divestment of its Prevacid 24HR business to Perrigo Company 
    • The divestment of assets relating to the Bialcol and Cibalgina brands in Italy to Vemedia 
    • The divestment of five over-the-counter dermatology brands and one pediatric cough remedy brand to the STADA Group 
    • The divestment of four established over-the-counter brands in eight countries to PharmaSGP
  • Swedish Orphan Biovitrum AB (publ) (Sobi™) on a variety of matters, including:
    • Its strategic licensing agreement with Selecta Biosciences for SEL-212, a phase-3 ready therapy for the treatment of chronic refractory gout, with a deal value of approximately US$730 million 
    • Its strategic licensing and collaboration agreement with Apellis Pharmaceuticals for co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan
  • Ligand Pharmaceuticals on its sale of Vernalis (R&D) Limited, a UK-based fragment and structure-based drug discovery research company, to HitGen
  • A consortium consisting of Astorg Asset Management, Nordic Capital, Novo Holdings and their portfolio company eResearchTechnologies on the data privacy aspects of its merger with Bioclinica, a technological and scientific leader in clinical imaging
  • Frontier Medicines on the data privacy aspects of its global partnership with AbbVie to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein target
  • Acino Pharma in relation to its purchase of a portfolio of over-the-counter and prescription pharmaceutical products in the Near East, Middle East, and Africa, for a total value in excess of US$200 million
  • Oasmia Pharmaceutical AB on its global strategic partnership for the development and commercialization of its proprietary anticancer product Apealea with Elevar Therapeutics, with a deal value of approximately US$698 million
  • Permira on data protection, contracts, regulatory, and IP matters related to the acquisition of Quotient Sciences, a provider of CDMO and CRO services to pharma and biotech companies
  • Quotient Sciences on its acquisition of Arcinova, the UK-based multiservice contract development and manufacturing organization
  • BC Partners on IP, contracts, data protection, and regulatory matters related to the acquisition of a majority interest in Synthon International Holding B.V., a global market leader in the development of complex generics
  • Various pharmaceutical and medical technology companies on agreements for the conduct of clinical trials in the EU, including GDPR compliance aspects of such trials
  • A medical technology and oncology company on the acquisition of an international group of hospitals and the potential use of data following acquisition
  • A medical technology company on its commercial launch strategy, including co-promotion and licensing agreements with clinics
  • A leading technology company on the classification of lifestyle and medical software and regulatory requirements for medical devices*
  • Various clients on GDPR implementation and compliance, e-commerce, and electronic marketing, including cross-border data transfers, standard contractual clauses, employee data access requests, breach notifications, and processor contracts

*Matter handled prior to joining Latham & Watkins 

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.